SynthesisBMC cardiovascular disorders2026
Efficacy and safety of dual antiplatelet therapy de-escalation in East Asian individuals following percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEast Asian patients with acute coronary syndrome (ACS) are more prone to bleeding complications than Western populations under comparable antithrombotic regimens. This pattern presents a considerable obstacle to the routine use of intensive dual antiplatelet therapy (DAPT) undergoing percutaneous coronary intervention (PCI). Consequently, the effectiveness and safety of DAPT de-escalation strategies tailored to this particular group of patients remain inadequately defined.
methodsAn extensive search of both Chinese and English literature databases was performed up to June 2025 to locate cohort studies and randomized controlled trials assessing the effectiveness and safety of de-escalating DAPT in East Asian individuals diagnosed with ACS. The primary outcomes included major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, and bleeding outcomes, with bleeding classified according to Bleeding Academic Research Consortium (BARC) criteria. Meta-analytical methods were applied using either fixed-effects or random-effects models, depending on data suitability.
resultsA total of nine studies were included in the analysis, consisting of five RCTs and four cohort studies, encompassing 10,263 patients overall. Compared to standard DAPT, the de-escalation approach was significantly linked to lower risks of BARC type 1 bleeding (RR = 0.52; 95% CI: 0.32–0.86; p = 0.011), BARC type ≥ 2 bleeding (RR = 0.47; 95% CI: 0.37–0.60; p < 0.001), and BARC type ≥ 3 events (RR = 0.61; 95% CI: 0.40–0.94; p = 0.026). Nonetheless, the comparison between de-escalation and standard regimens revealed no statistically meaningful difference in MACE risk (RR = 0.91; 95% CI: 0.70–1.19; p = 0.497). This result remained stable across the separate elements comprising the MACE composite outcome.
conclusionAmong East Asian patients with ACS, implementing a DAPT de-escalation strategy lowers bleeding risk without elevating ischemic events, suggesting a potentially favorable safety profile in East Asian patients. Further validation by RCTs is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.